Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal and optic nerve diseases with significant unmet medical need. The company operates within the ophthalmology and biotechnology industries and is publicly traded on the Nasdaq under the ticker KALA. As of its most recent public disclosures, KALA BIO does not generate product revenue and is primarily engaged in research and development activities.
Historically, the company was founded in 2009 as Kala Pharmaceuticals and initially focused on ocular surface diseases using its proprietary mucus-penetrating particle technology. It achieved FDA approvals for ophthalmic corticosteroid products before subsequently divesting its commercial assets. Following these transactions, the company rebranded as KALA BIO, Inc. and strategically refocused on retinal neuroprotection and regeneration, transitioning back to a development-stage profile.
Business Operations
KALA BIO’s operations are centered on drug discovery and clinical development, with its primary efforts directed toward advancing pipeline candidates targeting retinal and optic nerve degeneration. The company’s lead development program is KPI-012, a neuroprotective and regenerative biologic designed for intravitreal administration, currently evaluated for indications such as inherited retinal diseases and optic neuropathies.
The company conducts its operations primarily in the United States and relies extensively on third-party contract research organizations (CROs) for preclinical studies and clinical trial execution. Following the divestiture of its commercial-stage assets, KALA BIO no longer maintains manufacturing or sales infrastructure and operates with a streamlined organizational structure focused on capital preservation and pipeline advancement.
Strategic Position & Investments
Strategically, KALA BIO is positioned as a specialty ophthalmic R&D company targeting complex neurodegenerative eye diseases that lack effective treatments. Its growth strategy has centered on advancing KPI-012 through early-stage clinical development while maintaining flexibility to pursue strategic alternatives, including partnerships, licensing arrangements, or corporate transactions.
In recent years, the company completed the sale of its FDA-approved ophthalmic products and associated technologies to a large multinational ophthalmology company, materially altering its asset base and risk profile. As a result, KALA BIO’s investment focus has shifted toward selective internal development rather than portfolio expansion through acquisitions. Public disclosures indicate no material operating subsidiaries or joint ventures currently contributing to revenue.
Geographic Footprint
KALA BIO is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operational footprint is largely domestic, reflecting its status as a development-stage company without international commercial operations.
While clinical trials may involve investigational sites outside the U.S., the company does not report significant international infrastructure or overseas subsidiaries. Its global exposure is therefore limited and primarily indirect, arising from regulatory interactions and potential future clinical or strategic collaborations.
Leadership & Governance
KALA BIO is led by an executive team with experience in biotechnology company formation, drug development, and corporate strategy. Management has emphasized capital discipline, pipeline focus, and strategic optionality following the company’s transition away from commercial operations.
Key members of leadership include:
- Mark Iwicki – President and Chief Executive Officer
- Mark DeWitt – Chief Financial Officer
Publicly available filings indicate that governance is overseen by an independent board of directors with experience across pharmaceuticals, finance, and corporate restructuring. Information on additional executive roles and long-term leadership succession beyond the above positions is limited; data inconclusive based on available public sources.